You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 291 No. 7, February 18, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Pregnancy and Breast Feeding
 •Alert me on articles by topic

Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) in Colombian Women With Pre-eclampsia

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Worldwide, pre-eclampsia is a leading cause of maternal death, affecting 3% to 5% of all pregnancies.1 Recently, elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to pre-eclampsia and impaired endothelial function.2-5

Methods

To assess plasma ADMA concentration in pregnant women living in a high-risk area for pre-eclampsia, we sequentially enrolled, from November 2000 until February 2002, 160 women (67 women with pre-eclampsia [49 moderate and 19 severe cases] and 93 healthy pregnant controls) (Table 1) presenting in 4 Colombian study centers in a case-control study. All women were primigravid and younger than 25 years. Inclusion criteria for the pre-eclampsia group were: more than 20 weeks of gestation, blood pressure of 140/90 mm Hg or higher in 2 separate measurements, and proteinuria (>=0.3 g in 24 hours or a urine dipstick reading of >=2+ for protein with no . . . [Full Text of this Article]

Renke Maas, MD
maas@uke.uni-hamburg.de

Rainer H. Böger, MD; Edzard Schwedhelm, PhD
AG Klinische Pharmakologie
Institut für Experimentelle und Klinische Pharmakologie
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany

Juan P. Casas, MD; Patricio López-Jaramillo, MD, PhD
Instituto Colombiano de Investigaciones Biomédicas
Bucaramanga
Colombia

Norma Serrano, MD, MSc; Luis A. Díaz, MD
Universidad Autónoma de Bucaramanga
Bucaramanga



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: The role of the L-arginine-nitric oxide pathway in preeclampsia
Lopez-Jaramillo et al.
Therapeutic Advances in Cardiovascular Disease 2008;2:261-275.
ABSTRACT  

Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems
Palm et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H3227-H3245.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.